Securities code: 603990 securities abbreviation: Suzhou Medicalsystem Technology Co.Ltd(603990) Announcement No.: 2022-004
Suzhou Medicalsystem Technology Co.Ltd(603990)
Announcement on planning change of control and resumption of trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Suzhou Medicalsystem Technology Co.Ltd(603990) (hereinafter referred to as “the company”), as the controlling shareholder Mr. Weng Kang and the persons acting in concert Ms. Yan huanghong and Mr. Wang Jianhua are planning the change of the controlling shareholder and actual controller of the company, in view of the uncertainty of the matter, in order to ensure fair information disclosure, safeguard the interests of investors and avoid abnormal fluctuations in the company’s share price, the company has applied to Shanghai Stock Exchange, The trading of the company’s shares (stock abbreviation: Suzhou Medicalsystem Technology Co.Ltd(603990) , stock code: 603990) will be suspended from the opening of the market on Thursday, January 13, 2022. For details, please refer to Suzhou Medicalsystem Technology Co.Ltd(603990) announcement on suspension of planning control change (Announcement No.: 2022-001) disclosed by the company on January 13, 2022.
During the suspension period, the trading parties have further communicated and negotiated on the change of controlling shareholders and actual controllers, and have not signed relevant transaction agreements. The company is expected to be unable to resume trading from the morning of opening on January 17, 2022 (Monday). In order to ensure fair information disclosure, safeguard the interests of investors and avoid abnormal fluctuations in the company’s share price, the company applied to Shanghai Stock Exchange in accordance with relevant provisions such as the stock listing rules of Shanghai Stock Exchange (revised in January 2022) and the self regulatory guidelines for listed companies of Shanghai Stock Exchange No. 4 – suspension and resumption of trading, The trading of the company’s shares (securities code: 603990, securities abbreviation: Suzhou Medicalsystem Technology Co.Ltd(603990) ) will continue to be suspended since the opening of the market on Monday, January 17, 2022. It is expected that the suspension will not exceed 3 trading days. For details, see Suzhou Medicalsystem Technology Co.Ltd(603990) announcement on the progress of planning control change and continued suspension disclosed by the company on January 14, 2022 (Announcement No.: 2022-002).
On January 19, 2022, the company received the notice from Mr. Weng Kang, the controlling shareholder, the actual controller and the persons acting in concert, Ms. Yan huanghong, Mr. Wang Jianhua, and Mr. Fu Hong, the shareholder. Mr. Weng Kang, Ms. Yan huanghong, Mr. Wang Jianhua Mr. Fu Hong and Mianyang Anzhou Investment Holding Group Co., Ltd. signed the share transfer intention agreement on January 19, 2022, For details, see Suzhou Medicalsystem Technology Co.Ltd(603990) suggestive announcement on the signing of share transfer intention agreement by controlling shareholders, persons acting in concert and other shareholders and the proposed change of controlling shareholders and actual controllers disclosed by the company on January 20, 2022.
In accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange (revised in January 2022), the self regulatory guidelines for listed companies of Shanghai Stock Exchange No. 4 – suspension and resumption of trading, upon the application of the company to Shanghai Stock Exchange, the trading of the company’s shares will resume from the opening of the market on the morning of January 20, 2022.
The transaction plan can be formally implemented only after being reviewed by the competent authority and approved by the regulatory authority. Whether the transaction can obtain the above approval and the final approval time are uncertain. The company will continue to promote relevant work after the resumption of trading of shares, and timely perform the obligation of information disclosure in strict accordance with the requirements of relevant laws and regulations.
The information disclosure media designated by the company are China Securities News, Shanghai Securities News and the website of Shanghai Stock Exchange (www.sse. Com. CN), All information of the company shall be subject to the announcement published in the above designated media.
Please pay attention to the follow-up announcement and pay attention to the investment risk.
It is hereby announced.
Suzhou Medicalsystem Technology Co.Ltd(603990) board of directors January 20, 2022
